The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

RENO, Nev. (KOLO) - Northern Nevada Health System recently opened the new Northwest Specialty Hospital (6225 Sharlands Avenue ...

Doctors at Shanghai Ninth People's Hospital on Monday issued the first adult prescription in China for Takeda's innovative ...

Senator Joseph Addabbo partnered with Northwell LIJ Forest Hills to bring an interactive health and injury prevention event ...

Sebastien Beauzile, 21, became the first person in New York state to be made symptom-free of sickle cell disease after ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...